(1R,2R)-ethyl 2-(3-hydroxyphenyl)cyclopropanecarboxylate | 1435276-89-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (1R,2R)-ethyl 2-(3-hydroxyphenyl)cyclopropanecarboxylate
• 英文别名: Ethyl (trans)-2-(3-hydroxyphenyl)cyclopropane carboxylate；ethyl (1R,2R)-2-(3-hydroxyphenyl)cyclopropane-1-carboxylate
• CAS: 1435276-89-3
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: YANMSKHDZCCRIX-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)-2-(5,5-dimethyl-1-cyclopenten-1-yl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl 、 (1R,2R)-ethyl 2-(3-hydroxyphenyl)cyclopropanecarboxylate 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

  摘要：

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,

  DOI：

  10.1021/ml300427u
• 作为产物：
  描述：

  (3-溴苯氧基)(叔丁基)二苯基硅烷 在 四(三苯基膦)钯 、 dirhodium(II) tetracarboxylate 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 6.0h， 生成 (1R,2R)-ethyl 2-(3-hydroxyphenyl)cyclopropanecarboxylate
  参考文献：
  名称：

  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

  摘要：

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,

  DOI：

  10.1021/ml300427u

文献信息

• NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20230146210A1

  公开（公告）日：2023-05-11

  The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.